Table 2

Clinical responses at weeks 14 and 24*

		Week 14			Week 24
		Placebo	Infliximab 5 mg/kg	p Value	Placebo	Infliximab 5 mg/kg	p Value
*Values are shown as mean (SD) unless otherwise stated; †change or improvement from baseline.
Patients randomised (n)		100	100		100	100

ACR criteria
20% Improvement (%)†		11	58	<0.001	16	54	<0.001
50% Improvement (%)†		3	36	<0.001	4	41	<0.001
70% Improvement (%)†		1	15	<0.001	2	27	<0.001

Achieving PsARC (%)		27	77	<0.001	32	70	<0.001

Percentage improvement†
Number of swollen joints		−3.5 (68.9)	41.5 (81.1)	<0.001	23.5 (39.8)	58.0 (45.3)	<0.001
Number of tender joints		−13.0 (78.7)	47.4 (46.6)	<0.001	14.9 (36.5)	54.1 (45.2)	<0.001
CRP		−5.7 (64.0)	33.8 (66.6)	<0.001	−7.0 (55.0)	34.7 (67.5)	<0.001
Physician’s global assessment of disease activity (VAS)		12.5 (45.7)	51.7 (60.5)	<0.001	18.0 (55.9)	57.3 (46.8)	<0.001
Patient’s global assessment of disease activity (VAS)		1.3 (65.0)	39.7 (65.7)	<0.001	7.2 (45.4)	35.1 (74.4)	<0.001
Patient’s assessment of pain (VAS)		−11.8 (109.8)	39.6 (56.1)	<0.001	−10.0 (114.2)	37.4 (54.2)	<0.001
HAQ disability index		−18.4 (90.5)	48.6 (43.3)	<0.001	−19.4 (102.8)	46.0 (42.5)	<0.001
Duration of morning stiffness		−121.6 (694.7)	42.2 (101.6)	<0.001	−152.0 (882.6)	43.1 (103.9)	<0.001

Patients with ⩾1 dactylitis digits (%)		30	18	0.025	34	12	<0.001

Patients with enthesopathy (%)		34	22	0.016	37	20	0.002

PASI response
Patients with ⩾3% BSA affected with psoriasis (baseline)		87	83		87	83
⩾50% Improvement %)†		9	82	<0.001	8	75	<0.001
⩾75% Improvement (%)†		2	64	<0.001	1	60	<0.001
⩾90% Improvement (%)†		0	41	<0.001	0	39	<0.001

Percentage improvement in target lesion score†		−0.3 (37.4)	65.6 (35.9)	<0.001	−1.0 (40.1)	64.2 (43.9)	<0.001

Change in SF-36†
Physical component		1.1 (8.4)	9.1 (9.3)	<0.001	1.3 (8.2)	7.7 (9.8)	0.001
Mental component		−1.2 (9.3)	3.8 (11.1)	<0.001	0.4 (11.6)	3.9 (11.9)	0.047